GENUS ONCOLOGY - THE MUC1-C COMPANY
Company
Mission
About Us
Genus Overview
Management
Board of Directors
Scientific Advisory Board
Clinical and Research Partners
Contact
Sitemap
Why Target MUC1-C?
Clinical Trials
Summary
GO-203
Phase 2 AML Clinical Trial
The Science
Overview
MUC1 in Human Cancer: The Numbers
MUC1 in Human Cancer: Overexpression
Target for Carcinoma Stem-Like Cell
Target for Leukemia Stem Cell
MUC1-C is an Attractive Target for Reversing Immune Evasion
Intellectual Property
Programs
Pipeline
Targeting the Cytoplasmic Domain
Targeting the Extracellular Domain
Biomarker Program
News & Publications
News
Publications
>
Complete Listing
Role of MUC1-C in Signal Transduction
Role of MUC1-C in Epigenetic Regulation
Role of MUC1-C in Immune Evasion
MUC1 Vaccine
MUC1-C in Stem-like Cells
MUC1-C inhibitor formulated in Nanoparticles
MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
MUC1-C is a druggable target
Sitemap
Company
Mission
About Us
Genus Overview
Management
Board of Directors
Scientific Advisory Board
Clinical and Research Partners
Contact
Sitemap
Why Target MUC1-C?
Clinical Trials
Summary
GO-203
Phase 2 AML Clinical Trial
The Science
Overview
MUC1 in Human Cancer: The Numbers
Breast Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Esophagus Cancer
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Kidney Cancer
Bladder Cancer
Acute Myeloid Leukemia (AML)
Multiple Myeloma
MUC1 in Human Cancer: Overexpression
Target for Carcinoma Stem-like Cell
Target for Leukemia Stem Cell
MUC1-C is an Attractive Target for Reversing Immune Evasion
Intellectual Property
Programs
The Pipeline
Targeting the Cytoplasmic Domain
Targeting the Extracellular Domain
Biomarker Program
News and Publications
News
Publications
Complete Listing
Role of MUC1-C in Signal Transduction
Role of MUC1-C in Epigenetic Regulation
Role of MUC1-C in Immune Evasion
MUC1 Vaccine
MUC1-C in Stem-like Cells
MUC1-C inhibitor formulated in nanoparticles
MUC1-C is synergistic with chemotherapeutic and targeted drugs
MUC1-C is a druggable target
sitemap.xml
File Size:
15 kb
File Type:
xml
Download File
Company
Mission
About Us
Genus Overview
Management
Board of Directors
Scientific Advisory Board
Clinical and Research Partners
Contact
Sitemap
Why Target MUC1-C?
Clinical Trials
Summary
GO-203
Phase 2 AML Clinical Trial
The Science
Overview
MUC1 in Human Cancer: The Numbers
MUC1 in Human Cancer: Overexpression
Target for Carcinoma Stem-Like Cell
Target for Leukemia Stem Cell
MUC1-C is an Attractive Target for Reversing Immune Evasion
Intellectual Property
Programs
Pipeline
Targeting the Cytoplasmic Domain
Targeting the Extracellular Domain
Biomarker Program
News & Publications
News
Publications
>
Complete Listing
Role of MUC1-C in Signal Transduction
Role of MUC1-C in Epigenetic Regulation
Role of MUC1-C in Immune Evasion
MUC1 Vaccine
MUC1-C in Stem-like Cells
MUC1-C inhibitor formulated in Nanoparticles
MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
MUC1-C is a druggable target